First County Bank CT Sells 3,851 Shares of Kenvue Inc. $KVUE

First County Bank CT decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 27.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,208 shares of the company’s stock after selling 3,851 shares during the quarter. First County Bank CT’s holdings in Kenvue were worth $214,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in KVUE. Pittenger & Anderson Inc. bought a new stake in Kenvue during the first quarter valued at $30,000. TruNorth Capital Management LLC purchased a new position in Kenvue during the first quarter worth about $36,000. Truvestments Capital LLC purchased a new position in Kenvue during the first quarter worth about $37,000. Clal Insurance Enterprises Holdings Ltd grew its position in Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after buying an additional 1,287 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich grew its position in Kenvue by 120.6% during the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock worth $41,000 after buying an additional 929 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.5%

Shares of NYSE:KVUE opened at $16.34 on Tuesday. Kenvue Inc. has a 52-week low of $16.07 and a 52-week high of $25.17. The firm has a fifty day moving average of $20.25 and a 200 day moving average of $21.76. The firm has a market capitalization of $31.36 billion, a PE ratio of 22.08, a price-to-earnings-growth ratio of 2.36 and a beta of 0.83. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same period in the previous year, the business earned $0.32 earnings per share. The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, August 13th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 5.1%. Kenvue’s dividend payout ratio (DPR) is currently 112.16%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several recent analyst reports. Canaccord Genuity Group reduced their target price on Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Royal Bank Of Canada reduced their target price on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research report on Friday, August 8th. Citigroup restated a “neutral” rating on shares of Kenvue in a research report on Tuesday, September 23rd. Barclays cut their target price on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research report on Tuesday, July 15th. Finally, Redburn Partners set a $22.00 target price on shares of Kenvue in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $23.12.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.